Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Upper Tract Urothelial Carcinomas 1Lymphedema 1Leukemia, Myeloid, Acute 1Leukemia 1Breast Neoplasms 1Adenoma 1

Interventions

Cyclophosphamide 48fludarabine phosphate 36Methotrexate 26Cytarabine 24fludarabine 23Whole-Body Irradiation 23Rituximab 19Cyclosporine 19Antilymphocyte Serum 18Peripheral Blood Stem Cell Transplantation 17Filgrastim 17Busulfan 17Mycophenolic Acid 16Tacrolimus 15Azacitidine 15Alemtuzumab 15Radiotherapy 13Melphalan 13Imatinib Mesylate 13Etoposide 13Vincristine 11Methylprednisolone 11Cord Blood Stem Cell Transplantation 11Dexamethasone 10venetoclax 8Granulocyte Colony-Stimulating Factor 8Clofarabine 8thymoglobulin 7sargramostim 7nilotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia × Drug Evaluation × Clear all
NCT04840784 2023-10-11

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Terminated
9 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡